Bacteriophage Therapy Summit 2025

The 7th edition of the Hanson Wade Bacteriophage Therapy Summit will be held in Boston, USA from Tuesday 11th March till Thursday 13th March 2025.

What is the 7th Bacteriophage Therapy Summit and Why attend?

Step into the future of bacteriophage therapy at the 7th Bacteriophage Therapy Summit! Join an exclusive gathering of phage leaders, large pharma, and venture capitalists from Phiogen Pharma, Locus Biosciences, Armata Pharmaceuticals, PhagePro, Kinbzio, and more. For 3 days of content, immerse yourself in game-changing clinical insights and conversations designed to fast-track your bacteriophage research into meaningful and commercially viable therapies, going beyond AMR.

As the only global platform for industry-dominated phage drug developers, the 7th Bacteriophage Therapy Summit will return to Boston in 2025 to integrate 90+ phage experts to deep dive into:

• Navigating the regulatory and investment hurdles to accelerate the progress of bacteriophages through the clinic and achieve market approval from Nexabiome, TechnoPhage, and Sozo Ventures.
• Armata Pharmaceuticals showcase of clinical data from pivotal trials that prove the efficacy of bacteriophages in treating antibiotic-resistant infections.
• Leveraging machine learning to identify bacteriophage to target resistant bacteria with Locus Bioscience and Synpha Biosciences.
• Developing bacteriophage cocktails as rapid responses to a wide range of infectious diseases with Cytophage, Kinzbio and PhagePro.

Who will be at the 7th Bacteriophage Therapy Summit?

The summit will bring together 90+ phage experts, and individuals in positions and occupations of; Chiefs, CSOs, Directors, Heads, Managers, Professors and Scientists. Those who work in a diversity of fields such as; drug development, non-profit organizations, academia, solution and service providers.

Agenda for the 7th Bacteriophage Therapy Summit 2025

Tuesday 11th March 2025

Pre-conference Workshop

Wednesday 12th March 2025

Jason Clark Chief Scientific Officer at Nexabiome – Launching a National Framework for Compassionate Use of Bacteriophages

Sofia Corte-Real Chief Scientific Officer at TechnoPhage, and Jason Clark Chief Scientific Officer at Nexabiome – Dissecting the Guidance from Regulatory Bodies to Develop Bacteriophages Likely to Receive Approval

Nancy Tawil Chief Scientific Officer at PrecisioBiotix Therapeutics – Developing GMP Manufacture of Bacteriophages to Align with Regulatory Guidance

Nancy Tawil Chief Scientific Officer at PrecisioBiotix Therapeutics – Optimizing CMC to Develop High Purity, Stable & GMP Bacteriophages for Cost-Effective & Safe Use in Patient Treatment Regiments

Phil Huss Chief Scientific Officer at Synpha Biosciences – Data-driven Design of Next-Generation Bacteriophage Therapeutics

Kevin Neil Co-Founder & Chief Scientific Officer at TATUM Bioscience – Leveraging Engineered Bacteriophages to Target Cancer Cells & Induce an Immune Response Against Tumors

Yuliya Karpievitch AI & Data Analytics Team Lead at Phage WA – Optimizing Training Data & AI Models to Match Bacteriophages to Specifically Target Bacterial Strains

Taylor Penke Director Automation & AI at Locus Biosciences – Utilizing Machine Learning to Find a Matching Bacteriophage to Infectious Strain for Effective Treatment

Thursday 13th March 2025

Deborah Birx CEO at Armata Pharmaceuticals – Executing Definitive Pivotal Trials for Bacteriophages to Prove Clinical Efficacy

Steven Theriault CEO at Cytophage, and Minmin Yen Co-Founder & CEO at PhagePro – How Can Bacteriophage Therapies be Sustainable in the Market?

Carrie-Lynn Langlais Furr CEO at Bacteriophage & Drug Development Consultants – Rethinking the Business Model for Bacteriophages to Develop Effective Therapies to Take to Market

Minmin Yen Co-Founder & CEO at PhagePro – Developing an Off-the-shelf Bacteriophage Cocktail Invention for Cholera in Low- & Middle-Income Countries

Steven Theriault CEO at Cytophage – Exploring Personalized vs Off-the-shelf Phage Therapies as Most Effective Therapies to Achieve Market Approval

Gregorio Iraola CEO at Kinzbio – Investigating Jumbo Bacteriophages as Personalized & Off-the-shelf Therapies to Difficult-to-Treat Infections

Dean Scholl CEO at Pylum Bioscience – Engineered Phage Tail-Like Bacteriocins as Human Therapeutics

Kristof Van Emelen CEO at Obulytix – Developing Engineered Lysin Proteins to Combat Antibiotic-Resistant Bacteria

View past events by Hanson Wade